Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Gains from Investment Securities (2022 - 2026)

HeartSciences (HSCS) has disclosed Gains from Investment Securities for 4 consecutive years, with $467.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 99.33% year-over-year to $467.0, compared with a TTM value of $467.0 through Oct 2025, down 99.81%, and an annual FY2025 reading of $173659.0, up 48543.98% over the prior year.
  • Gains from Investment Securities was $467.0 for Q4 2025 at HeartSciences, down from $125000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $510431.0 in Q4 2022 and bottomed at -$150967.0 in Q2 2023.
  • Average Gains from Investment Securities over 4 years is $91826.3, with a median of $68637.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities tumbled 5799.02% in 2023, then soared 241.36% in 2025.
  • Year by year, Gains from Investment Securities stood at $510431.0 in 2022, then crashed by 80.49% to $99564.0 in 2023, then tumbled by 30.01% to $69686.0 in 2024, then plummeted by 99.33% to $467.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for HSCS at $467.0 in Q4 2025, $125000.0 in Q3 2025, and $173659.0 in Q2 2025.